Teplizumab-mzwv (Tzield) Coverage Criteria
Customize your policy alerts
Sign up for MVP Health Care Policy 110 alerts
Get alerted when Policy 110 changes without checking for updates manually.
Monitor payer policy activity
Prior authorization and medical-benefit coverage for intravenous teplizumab-mzwv (Tzield) for Medicare Part B members age 8 years and older with stage 2 type 1 diabetes who meet specified clinical, laboratory, dosing, and infection-related requirements.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.